Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Ironwood Signs Pact With Spanish Firm

by Rick Mullin
May 11, 2009 | A version of this story appeared in Volume 87, Issue 19

Ironwood Pharmaceuticals, based in Cambridge, Mass., has licensed to Spain's Laboratorios Almirall the European rights to develop and commercialize linaclotide, its investigational compound for irritable bowel syndrome. Almirall will pay $40 million up front plus potential precommercial licensing and milestone payments of up to $95 million. Ironwood would also receive royalties on sales in Europe.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.